Form 4: Ventyx Biosciences COO Acquires 145,000 Stock Options

Ventyx Biosciences' Chief Operating Officer, Matthew Richard Moore, was granted 145,000 stock options on January 2, 2025.

Summary

• Matthew Richard Moore, the Chief Operating Officer of Ventyx Biosciences, Inc., was granted 145,000 stock options on January 2, 2025.
• The options have an exercise price of $2.14 per share.
• The options vest monthly over a four-year period, with one forty-eighth of the total shares vesting each month starting from the vesting commencement date of January 2, 2025.
• The options expire on January 2, 2035.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns management interests with shareholders. There is no indication of any negative or unexpected events.

Positives

• The granting of stock options to the COO aligns his interests with the long-term success of the company.
• The vesting schedule encourages continued service and commitment from the COO.

Industry Context

Stock option grants are a common practice in the biotechnology industry to incentivize and retain key executives.

Comparison to Industry Standards

• Stock option grants are a standard form of compensation for executives in the biotech industry, similar to companies like Amgen, Gilead, and Regeneron.
• The vesting schedule of 1/48th per month is a typical vesting schedule for stock options.

Stakeholder Impact

• The stock option grant may positively impact shareholder value by incentivizing the COO to improve company performance.

Key Dates

Keywords

stock options, insider trading, executive compensation, Ventyx Biosciences, VTYX, Matthew Richard Moore, Chief Operating Officer